England just announced the world's first gonorrhoea vaccination programme starting August 2025. Why isn't Europe joining in?

Tejal Somvanshi

Gonorrhoea cases in England hit 85,000 in 2023 - the highest since records began in 1918 and triple the numbers from 2012.

Photo Source: NIAID (CC BY 2.0)

The vaccine isn't new - it's the meningitis B vaccine (4CMenB/Bexsero) that scientists found also works against gonorrhoea because the bacteria are genetically similar.

Photo Source: NIAID (CC BY 2.0)

Studies show the vaccine offers 30-42% protection against gonorrhoea - not perfect but enough to prevent 100,000 cases over a decade and save the NHS £7.9 million.

Photo Source: United Nations Photo (CC BY-NC-ND 2.0)

Antibiotic-resistant "super gonorrhoea" is a growing threat - UKHSA reported 17 resistant cases and 9 extensively drug-resistant cases in just 15 months.

Photo Source: Pearlsa (CC BY-NC 2.0)

The programme targets high-risk groups: primarily gay and bisexual men with multiple partners, sex workers, and people with histories of STIs.

Photo Source: Wyatt Fisher 123 (CC BY-SA 2.0)

When patients come for their gonorrhoea jab, they'll also be offered vaccines for mpox, Hepatitis A and B, and HPV - maximizing protection in one visit.

Photo Source: Nataliya Vaitkevich (Pexels)

"This could cut 40% of new gonorrhoea cases," says Richard Angell from Terrence Higgins Trust. But why hasn't the EU announced similar plans?

Photo Source: Marco (Pexels)

European health authorities might be waiting for vaccines with higher effectiveness or conducting their own cost-benefit analyses before committing.

Photo Source: Rawpixel (CC 1.0)

Meanwhile, pharmaceutical companies are racing to develop dedicated gonorrhoea vaccines that could offer better protection - with GSK's candidate already fast-tracked by the US FDA.

Photo Source: Asian Development Bank (CC BY-NC 2.0)